GSK Achieves Survival Edge for Blenrep in Myeloma, Surpassing J&J's Darzalex with New Phase 3 Data

GSK's Blenrep has demonstrated a strong survival benefit in the treatment of multiple myeloma, outperforming Johnson & Johnson's Darzalex in the phase 3 DREAMM-7 trial. This trial revealed that Blenrep, in combination with bortezomib and dexamethasone, significantly extends patient survival compared to the same combination with Darzalex[1][2]. With a 60% greater reduction in the risk of death or disease progression, this new data marks a significant turn for Blenrep, which was previously withdrawn due to a failed trial[2]. GSK aims to finalize new filings in the U.S. and EU, hopeful that this compelling survival benefit will secure substantial market adoption and position Blenrep as a promising second-line therapy[1].